Company Intelligence Profile
4basecare Onco Solutions Private Limited
Bengaluru-based precision-oncology genomics company (4baseCare brand), an Indian subsidiary of a foreign parent, offering NGS-based cancer biomarker and gene-panel testing.
Last updated 4 August 2026
4basecare Onco Solutions Private Limited is a Bengaluru-based precision-oncology genomics company offering next-generation sequencing-based cancer biomarker and gene-panel testing. The company reported operating revenue of approximately ₹3.12 crore in FY2025, down about 74% year-on-year, and has raised cumulative funding of around $25.9 million across multiple rounds as of 2026.
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
See what AICA knows about 4basecare Onco Solutions
Deeper analysis, financial signals and peer comparisons.
Company Identity
| Registered name | 4basecare Onco Solutions Private Limited |
|---|---|
| CIN | U85100KA2020FTC138091 |
| PAN | Not available in the public sources reviewed. |
| Status | Active |
| Listing | No — unlisted private company (subsidiary of a foreign company) |
| Incorporated | 03 September 2020 |
| ROC | RoC-Bangalore (Karnataka) |
| Sector (NIC) |
|
| Registered address | c/o Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase 1, Bangalore, Karnataka, India – 560100 |
| Authorized capital | ₹40.0 lakh |
| Paid-up capital | ₹35.64 lakh |
Business Overview
- 4Basecare Onco Solutions (brand: 4baseCare) is a precision-oncology company using next-generation sequencing (NGS), genomics and digital-health tools for cancer biomarker testing and therapy selection
- Its genomic panels include Indiegene, marketed as an India-population-specific cancer gene panel for biomarker testing
- Founders Hitesh Goswami and Kshitij Rishi started the 4baseCare brand in 2018; this Indian legal entity was incorporated in September 2020 as a subsidiary of a foreign parent
- Reported headcount ~156 (Mar 2025)
Directors
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Kshitij Datta Rishi | 06442992 | - | 03 Sep 2020 |
Financials
- Standalone (unaudited aggregation from directory sources; treat as indicative, not primary filings)
- FY2025 (year ended 31 Mar 2025): Operating revenue ≈ ₹3.12 crore, reported down ~74% YoY; flag for confirmation
Funding
- CAUTION — entity-attribution trap
- Public funding coverage is reported against the "4baseCare" brand/group, NOT confirmed against this specific CIN (U85100KA2020FTC138091); the recipient may be a sister/parent entity (e.g., 4Basecare Genomics Pvt Ltd or the foreign parent)
- Brand-level rounds reported: pre-Series A ~$2M (consortium of VCs, via PR Newswire)
- Series A $6M led by Yali Capital (GenomeWeb, 2023-24)
- Series B first close Rs 90 crore (investors incl. Ashish Kacholia, Lashit Sanghvi, Yali Capital)
- Series B second close/top-up Rs 38 crore led by growX Ventures and Infosys, taking Series B to ~Rs 128 crore (~$13.3M) [Entrackr, Jun 2026]
- Tracxn cites cumulative ~$25.9M across ~8 rounds. [GenomeWeb, Entrackr, SiliconIndia, PR Newswire]
Charges & Loans
Not available in the public sources reviewed.
Competitors
Frequently Asked Questions
What does 4basecare Onco Solutions Private Limited do?
What is the CIN of 4basecare Onco Solutions Private Limited?
Where is 4basecare Onco Solutions Private Limited registered?
When was 4basecare Onco Solutions Private Limited incorporated?
Recur Market
Which lenders fit a company like 4basecare Onco Solutions Private Limited?
Answer a few questions about your business and see which banks and NBFCs match, with indicative rates.
More on Recur Club
Recently added companies
Lenders on Recur Club
Explore on Recur Club
More from Recur Club
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.